HSIC vs. ROIV, RGEN, EHC, EXAS, TFX, CTLT, CHE, QGEN, GMED, and ELAN
Should you be buying Henry Schein stock or one of its competitors? The main competitors of Henry Schein include Roivant Sciences (ROIV), Repligen (RGEN), Encompass Health (EHC), Exact Sciences (EXAS), Teleflex (TFX), Catalent (CTLT), Chemed (CHE), Qiagen (QGEN), Globus Medical (GMED), and Elanco Animal Health (ELAN). These companies are all part of the "medical" sector.
Roivant Sciences (NASDAQ:ROIV) and Henry Schein (NASDAQ:HSIC) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Henry Schein received 325 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 75.00% of users gave Roivant Sciences an outperform vote while only 51.54% of users gave Henry Schein an outperform vote.
Roivant Sciences has a net margin of 3,624.14% compared to Roivant Sciences' net margin of 3.12%. Roivant Sciences' return on equity of 13.51% beat Henry Schein's return on equity.
Roivant Sciences has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Henry Schein has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Henry Schein has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.
64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 4.6% of Roivant Sciences shares are owned by company insiders. Comparatively, 1.1% of Henry Schein shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Roivant Sciences currently has a consensus price target of $16.90, suggesting a potential upside of 50.49%. Henry Schein has a consensus price target of $81.73, suggesting a potential upside of 9.55%. Given Henry Schein's stronger consensus rating and higher possible upside, equities research analysts plainly believe Roivant Sciences is more favorable than Henry Schein.
In the previous week, Henry Schein had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Henry Schein and 3 mentions for Roivant Sciences. Henry Schein's average media sentiment score of 0.94 beat Roivant Sciences' score of 0.77 indicating that Roivant Sciences is being referred to more favorably in the media.
Summary
Roivant Sciences beats Henry Schein on 10 of the 18 factors compared between the two stocks.
Get Henry Schein News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Henry Schein Competitors List
Related Companies and Tools
